Almirall Has $1.1 Billion Ready for Skin Health Deals, CEO Says.

Almirall's leverage levels stand at 1.3 times its Ebitda, giving the firm scope to contemplate an acquisition of the size it now has in mind, Nazzi said. (Bloomberg) -- Spanish pharmaceutical firm Almirall SA has 1 billion euros ($1.1 billion) on hand to spend on acquisitions to beef up its offering of skin treatments, Chief Executive Officer Gianfranco Nazzi said. [Extracted from the article]

Copyright of Bloomberg.com is the property of Bloomberg, L.P. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)